Annual report
9987.TEDINET S100YFRU
Period2025-04-01 → 2026-03-31
Filed2026-06-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.49T | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥2.40T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥2.39T | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.24T | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥36.4bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥37.1bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥39.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥38.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥38.4bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.4bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥54.3bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥50.3bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥38.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥34.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.0bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.4bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥38.1bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥34.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥1.16T | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.11T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.23T | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.15T | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.14T | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥739.8bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥706.4bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥416.0bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥407.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥416.4bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥418.1bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥116.7bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥102.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥131.6bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥118.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥198.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥132.9bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥168.2bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥33.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥65.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥87.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥37.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥9.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥12.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥10.3bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥46.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥1.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥33.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥35.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥31.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥26.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥11.6bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥545.54 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥454.58 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥357.88 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥163.19 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥6,148.58 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,651.56 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥5,361.96 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,970.38 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,749.59 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.0% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.3% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.4% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 12,717 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 12,923 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 13,086 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 13,429 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 14,032 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥2.30T | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥2.21T | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥2.19T | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.12T | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.04T | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥22.7bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥23.9bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥28.2bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥28.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥28.5bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.7bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥14.9bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥40.0bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥36.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥29.2bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥25.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥21.1bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥14.9bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥13.8bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.04T | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥1.02T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥1.13T | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.05T | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.03T | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥770.9bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥749.6bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥269.2bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥271.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥286.6bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥290.8bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥302.5bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥79.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥61.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥418.27 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339.09 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥259.73 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.97 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥156.55 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥100 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥72 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,979.89 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,768.25 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,691.98 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,515 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,440.25 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 25.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.3% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.7% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.5% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.8% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.6% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 72,167,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 72,167,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 77,740,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 82,831,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 103,344,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,991 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 3,082 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 3,176 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 3,232 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 3,430 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 90
| Segment | Item | Period | Value |
|---|---|---|---|
| The Community Healthcare And Nursing Care Support Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥658m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥735m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | employees | at 2026-03-31 | 3322 pure |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥93.9bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥93.9bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥14m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment assets | at 2026-03-31 | ¥42.3bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.5bn |
| The Healthcare Product Development Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| The Healthcare Product Development Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥671m |
| The Healthcare Product Development Businessreportable segment | employees | at 2026-03-31 | 861 pure |
| The Healthcare Product Development Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥51.6bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥11.9bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥39.7bn |
| The Healthcare Product Development Businessreportable segment | segment assets | at 2026-03-31 | ¥67.8bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥830m |
| The Healthcare Related Services Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥201m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥520m |
| The Healthcare Related Services Businessreportable segment | employees | at 2026-03-31 | 688 pure |
| The Healthcare Related Services Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥43.0bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥24.6bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥18.3bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2026-03-31 | ¥38.0bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.3bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥17.3bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥10.4bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2026-03-31 | 7834 pure |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.40T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.35T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥51.6bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2026-03-31 | ¥1.04T |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥31.5bn |
| The Specialty Drug Contract Distribution Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥17m |
| The Specialty Drug Contract Distribution Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥12m |
| The Specialty Drug Contract Distribution Businessreportable segment | employees | at 2026-03-31 | 12 pure |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥436.1bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥6.8bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥429.3bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment assets | at 2026-03-31 | ¥93.3bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥12.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥3.03T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥2.49T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥539.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥1.28T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥36.3bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥970m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥803m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥94.4bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥94.4bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥15m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment assets | at 2025-03-31 | ¥41.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| The Healthcare Product Development Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥800m |
| The Healthcare Product Development Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥509m |
| The Healthcare Product Development Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥52.6bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.7bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥40.9bn |
| The Healthcare Product Development Businessreportable segment | segment assets | at 2025-03-31 | ¥66.0bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| The Healthcare Related Services Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥311m |
| The Healthcare Related Services Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥501m |
| The Healthcare Related Services Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥42.2bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.3bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥17.9bn |
| The Healthcare Related Services Businessreportable segment | segment assets | at 2025-03-31 | ¥33.0bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| The Pharmaceutical Distribution Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥18.8bn |
| The Pharmaceutical Distribution Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥10.2bn |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.31T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.26T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥50.8bn |
| The Pharmaceutical Distribution Businessreportable segment | segment assets | at 2025-03-31 | ¥987.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥31.9bn |
| The Specialty Drug Contract Distribution Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥6m |
| The Specialty Drug Contract Distribution Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥10m |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥295.5bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| The Specialty Drug Contract Distribution Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥289.1bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment assets | at 2025-03-31 | ¥58.2bn |
| The Specialty Drug Contract Distribution Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥845m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥2.80T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥2.40T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥398.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥1.19T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥37.0bn |
| The Pharmaceutical Distribution Businessreportable segment | employees | at 2026-03-31 | 2991 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,132
| Item | Context | Value | Unit |
|---|---|---|---|
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row31Member | Original text (Japanese)無(注)２ | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)㈱ケアネット | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row32Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)塩野義製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row33Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)㈱ツルハホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row34Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Original text (Japanese)ウエルシアホールディングス㈱(注)３ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row35Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Original text (Japanese)テルモ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row36Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Original text (Japanese)久光製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row37Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row3Member | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)㈱サンキ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)㈱アスティス | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | Original text (Japanese)㈱翔薬 | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | Original text (Japanese)㈱スズケン沖縄薬品 | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row5Member | Original text (Japanese)ナカノ薬品㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row6Member | Original text (Japanese)㈱スズケン岩手 | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row7Member | Original text (Japanese)㈱エス・ディ・ロジ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row8Member | Original text (Japanese)㈱三和化学研究所 | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row9Member | Original text (Japanese)㈱ユニスマイル | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row10Member | Original text (Japanese)中央運輸㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row11Member | Original text (Japanese)サンキ・ウエルビィ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row12Member | Original text (Japanese)㈱エスケアメイト | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row13Member | Original text (Japanese)ケンツメディコ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row14Member | Original text (Japanese)㈱エスマイル | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |